White line = price, green steps = our fair value per fiscal year. As of Nov 21, 2026.
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease.
Show moreShow less
The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases.
The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy.
The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S (0QIU) currently trades at kr 264.13, while our model-based Fair Value estimate is kr 404.62, implying the stock looks roughly 35% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of kr 426.27 per share, and 15 of the 26 models we run sit above the kr 264.13 price.
Bear case: the Growth DCF group reads lowest at kr 203.41, and 11 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: kr 195.73 (bear) to kr 554.16 (bull), the price of kr 264.13 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Novo Nordisk A/S reported revenue of 141B DKK in FY2021 versus 112B DKK in FY2017, a compound +6.0%/yr. Reported net income was 47.8B DKK in FY2021, compounding +5.8%/yr from FY2017.
Key figures
Market cap 19.9B DKK (≈ $2.9B) · P/E ratio 0.4 · P/S ratio 0.09 · EPS (TTM) kr 21.50 · Dividend yield 4.4% · Net margin 33.4% · Return on equity 81.5% · Return on assets (EBIT) 40.0% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (medium confidence).
What moves the price
The share trades about 33% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −3% fair-value upside, at 53%, 0QIU screens cheaper than that median.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF
kr 90.98
kr 186.95
kr 369.88
74
5Y EBITDA Exit
kr 243.09
kr 483.98
kr 786.71
72
EPV
kr 219.86
kr 265.39
kr 306.78
72
All 26 models by family
DCF Models
FCF DCF
kr 90.98
kr 186.95
kr 369.88
74
Owner Earnings
kr 120.08
kr 241.39
kr 472.63
71
5Y Revenue Exit
kr 115.04
kr 224.83
kr 373.99
69
5Y EBITDA Exit
kr 243.09
kr 483.98
kr 786.71
72
5Y P/E Exit
kr 260.48
kr 519.17
kr 814.06
68
10Y Revenue Exit
kr 101.67
kr 206.77
kr 367.36
63
10Y EBITDA Exit
kr 195.73
kr 404.62
kr 724.74
64
10Y P/E Exit
kr 207.78
kr 431.49
kr 748.43
60
Earnings-Based
Graham-Dodd
kr 156.81
kr 679.13
kr 928.54
61
Lynch FV
kr 231.39
kr 330.56
kr 429.74
58
PEG = 1.0
kr 231.39
kr 330.56
kr 429.74
55
EPV
kr 219.86
kr 265.39
kr 306.78
72
Dividend Discount
Gordon GGM
kr 167.25
kr 392.46
kr 729.85
62
DDM Multi-Stage
kr 167.25
kr 307.59
kr 404.42
64
Multiples
P/E Multiple
kr 380.49
kr 507.32
kr 634.15
61
P/S Multiple
kr 182.64
kr 243.51
kr 304.40
56
P/B Multiple
kr 48.62
kr 64.83
kr 81.03
53
EV/EBIT
kr 342.89
kr 465.03
kr 587.17
64
EV/EBITDA
kr 330.19
kr 448.09
kr 566.00
66
EV/Revenue
kr 122.59
kr 185.21
kr 247.83
52
Asset-Based
NCAV (Graham)
kr 7.20
kr 9.66
kr 14.41
52
Growth DCF
Growth DCF
kr 91.65
kr 185.44
kr 369.49
72
Rev-Margin DCF
kr 115.04
kr 221.39
kr 355.60
70
Economic Profit
Residual Income
kr 145.80
kr 206.35
kr 478.93
68
ROIC Compounder
kr 247.36
kr 335.99
kr 448.35
70
Growth Earnings
Growth-Adj P/E
kr 298.40
kr 426.27
kr 554.16
66
Models of NOVO-B.CO, converted to this listing with the same factor as the fair value.
Open the full fair value analysis →
Overall quality
58/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability
84
How much profit the company makes from its sales and capital
Quality Growth
31
Are margins and returns getting better?
Cashflow
48
Do the profits arrive as real cash?
Financial strength
66
Debt, balance sheet and risk of trouble
Investment
0
Does it invest with discipline instead of growing at any price?
Low Volatility
65
How calm the share price moves, does not count
Price momentum
26
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high
22
Distance to the 52-week high, does not count
New shares
84
Buys back shares or issues new ones?
Open the full quality analysis →
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.
Pick a strategy and jump into the live analysis with that exact screen applied.
Is Novo Nordisk A/S (0QIU) overvalued or undervalued?
As of Nov 21, 2026, our model estimates a fair value of kr 404.62 versus a price of kr 264.13, about +53% upside (undervalued).
What is the fair value of 0QIU?
Our model-based fair value for Novo Nordisk A/S is kr 404.62 (as of Nov 21, 2026), built from audited fundamentals. The current price: kr 264.13.
What is the quality score of 0QIU?
Novo Nordisk A/S has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Novo Nordisk A/S (0QIU)?
We do not set a price target; the yardstick is the fair value of kr 404.62 (as of Nov 21, 2026) from 26 valuation models. Cautious scenario kr 195.73, optimistic scenario kr 554.16. It is a calculation from audited fundamentals, not an analyst target.
What is the Novo Nordisk A/S stock forecast for 2026?
Our models put fair value at kr 404.62, about +53% upside versus a price of kr 264.13 (undervalued). Cautious scenario kr 195.73, optimistic scenario kr 554.16. The calculation is refreshed regularly with new filings.
What is the revenue of Novo Nordisk A/S (0QIU)?
Novo Nordisk A/S reported trailing-twelve-month revenue of about 201B DKK (latest available figure, as of Nov 21, 2026).
Does Novo Nordisk A/S pay a dividend?
Novo Nordisk A/S currently shows a dividend yield of 4.43% relative to its recent price (as of Nov 21, 2026).
How much is the dividend of Novo Nordisk A/S (0QIU) and when is the ex-dividend date?
Novo Nordisk A/S pays a dividend of kr 11.70 per share a year, a dividend yield of 4.4%. The last ex-dividend date was Aug 14, 2026. A dividend has been paid every year since at least 2003. The payout ratio is 54.4% of earnings. Free cash flow covers the dividend 1.72 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What is the intrinsic value of Novo Nordisk A/S (0QIU)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Novo Nordisk A/S it is kr 404.62 per share (as of Nov 21, 2026), against a price of kr 264.13. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Novo Nordisk A/S stock overvalued or undervalued in 2026?
As of Nov 21, 2026, 0QIU trades below its calculated fair value: price kr 264.13, fair value kr 404.62, a gap of about +53% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0QIU?
No. The price is what the market pays today (kr 264.13); the fair value is what the company's own numbers justify (kr 404.62). For Novo Nordisk A/S the two are kr 140.49 per share apart. That gap is exactly why we show both numbers side by side.
How much is Novo Nordisk A/S worth?
The market values Novo Nordisk A/S at about 19.9B DKK (market capitalisation, as of Nov 21, 2026). Per share that is kr 264.13; our models calculate a fair value of kr 404.62 per share.
What do the bullish and bearish scenarios say about 0QIU?
Our models span a range for Novo Nordisk A/S: cautious scenario kr 195.73, base kr 404.62, optimistic kr 554.16 per share (as of Nov 21, 2026, price kr 264.13). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0QIU from its 52-week high?
Novo Nordisk A/S trades at kr 264.13, about 33% below its 52-week high of kr 392.13 and 17% above the low of kr 225.35 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of kr 404.62 is for.
Which stocks are comparable to Novo Nordisk A/S?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Novo Nordisk A/S stock attractive at the current price?
The data as of Nov 21, 2026: price kr 264.13, calculated fair value kr 404.62 (+53%), Quality Score 58/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0QIU calculated?
We run Novo Nordisk A/S through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of kr 404.62 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 10.1% above its aggregate fair value. Novo Nordisk A/S currently trades 35% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on
is it worth investing now.
What is the share price of Novo Nordisk A/S (0QIU)?
The closing price on Nov 20, 2026 was kr 264.13. Our model-based fair value is kr 404.62, about +53% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Novo Nordisk A/S right now?
The model range is unusually wide (kr 195.73 to kr 554.16). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (58/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Novo Nordisk A/S
How large is the market capitalisation of Novo Nordisk A/S (0QIU)?
The market capitalisation of Novo Nordisk A/S is 19.9B DKK (≈ $2.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Novo Nordisk A/S (0QIU)?
The price-to-earnings ratio of Novo Nordisk A/S is 0.4 (as of Oct 19, 2026). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Novo Nordisk A/S (0QIU)?
The price-to-sales ratio of Novo Nordisk A/S is 0.09 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Novo Nordisk A/S (0QIU)?
Earnings per share at Novo Nordisk A/S are kr 21.50 (price ÷ EPS = P/E 0.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Novo Nordisk A/S (0QIU)?
The dividend yield of Novo Nordisk A/S is 4.4% (payout 54.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Novo Nordisk A/S (0QIU)?
The net margin of Novo Nordisk A/S is 33.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Novo Nordisk A/S (0QIU)?
The return on equity (ROE) of Novo Nordisk A/S is 81.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Novo Nordisk A/S (0QIU)?
On an EBIT basis the return on assets of Novo Nordisk A/S is 40.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Novo Nordisk A/S (0QIU)?
The operating margin of Novo Nordisk A/S is 43.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Novo Nordisk A/S (0QIU)?
Revenue at Novo Nordisk A/S is growing 31.6% in the last quarter versus the same quarter a year earlier (3y avg +8.0%). How much revenue grew in the last quarter versus the same quarter a year earlier (YoY). The 3-year average next to it puts the single quarter in context.
How fast are earnings growing at Novo Nordisk A/S (0QIU)?
Earnings per share at Novo Nordisk A/S are growing 47.3% in the last quarter versus the same quarter a year earlier. How much earnings per share grew in the last quarter versus the same quarter a year earlier.